The bioactivation of tramadol by CYP2D6 is an important source of variability due to drug conversation. The analgesic efficacy of tramadol is often considerably minimized by CYP2D6 inhibitors, such as some SSRIs or terbinafine [114, 115].The extent of proof to help the usage of tramadol and tapentadol in musculoskeletal or cancer-associated Continu